Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Apr 26;9(5):427.
doi: 10.3390/nu9050427.

Tradeoff-in-the-Nephron: A Theory to Explain the Primacy of Phosphate in the Pathogenesis of Secondary Hyperparathyroidism

Affiliations

Tradeoff-in-the-Nephron: A Theory to Explain the Primacy of Phosphate in the Pathogenesis of Secondary Hyperparathyroidism

Kenneth R Phelps. Nutrients. .

Abstract

Chronic kidney disease (CKD) causes secondary hyperparathyroidism (SHPT). The cardinal features of SHPT are persistence of normocalcemia as CKD progresses and dependence of the parathyroid hormone concentration ([PTH]) on phosphate influx (IP). The tradeoff-in-the-nephron hypothesis integrates these features. It states that as the glomerular filtration rate (GFR) falls, the phosphate concentration ([P]CDN) rises in the cortical distal nephron, the calcium concentration ([Ca]CDN) in that segment falls, and [PTH] rises to maintain normal calcium reabsorption per volume of filtrate (TRCa/GFR). In a clinical study, we set GFR equal to creatinine clearance (Ccr) and IP equal to the urinary excretion rate of phosphorus (EP). We employed EP/Ccr as a surrogate for [P]CDN. We showed that TRCa/Ccr was high in patients with primary hyperparathyroidism (PHPT) and normal in those with SHPT despite comparably increased [PTH] in each group. In subjects with SHPT, we examined regressions of [PTH] on EP/Ccr before and after treatment with sevelamer carbonate or a placebo. All regressions were significant, and ∆[PTH] correlated with ∆EP/Ccr in each treatment cohort. We concluded that [P]CDN determines [PTH] in CKD. This inference explains the cardinal features of SHPT, much of the evidence on which other pathogenic theories are based, and many ancillary observations.

Keywords: calcium; chronic kidney disease; cortical distal nephron; distal convoluted tubule; parathyroid hormone; phosphate; secondary hyperparathyroidism.

PubMed Disclaimer

Conflict of interest statement

The author declares no conflict of interest.

Figures

Figure 1
Figure 1
Plots of ECa/Ccr and TRCa/Ccr against [PTH] in control subjects and patients with primary and secondary hyperparathyroidism (PHPT and SHPT). All data are derived from morning fasting specimens of urine and serum or plasma. Circles represent normal controls. Triangles and diamonds represent patients with PHPT and SHPT (CKD), respectively. Frame (a) shows that the lowest recorded values of ECa/Ccr in controls were compatible with normal [PTH]. It also shows that a minority of patients with CKD exhibited high ECa/Ccr and high [PTH] simultaneously. Frame (b) shows that [PTH] capable of causing high TRCa/Ccr in patients with PHPT maintained normal TRCa/Ccr in patients with CKD. Reproduced from [16] with permission of the publisher (Dustri-Verlag). ECa, Urinary excretion rate of calcium, mass/time; Ccr, Creatinine clearance (volume/time); TRCa, Rate of tubular reabsorption of calcium, mass/time; PTH, Parathyroid hormone; CKD, Chronic kidney disease.
Figure 2
Figure 2
Relationship of [PTH] to EP/Ccr in sevelamer and placebo recipients. Squares pertain to the sevelamer group and diamonds to the placebo group. Graphs (a) and (c) show regressions of [PTH] on EP/Ccr before and after administration of sevelamer carbonate for four weeks. Graphs (b) and (d) show the same regressions before and after administration of a placebo for four weeks. Graphs (e) and (f) show regressions of ∆[PTH] on ∆EP/Ccr in the sevelamer and placebo groups, respectively, where “∆” = change during treatment. All regressions are statistically significant. Adapted from [17] with permission of the publisher (Dustri-Verlag). EP, urinary excretion rate of phosphorus, mass/time; Ccr, creatinine clearance, volume/time.

Similar articles

Cited by

References

    1. Pitts T.O., Piraino B.H., Mitro R., Chen T.C., Segre G.V., Greenberg A., Puschett J.B. Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure. J. Clin. Endocrinol. Metab. 1988;67:876–881. doi: 10.1210/jcem-67-5-876. - DOI - PubMed
    1. Reichel H., Deibert B., Schmidt-Gayk H., Ritz E. Calcium metabolism in early chronic renal failure: Implications for the pathogenesis of hyperparathyroidism. Nephrol. Dial. Transplant. 1991;6:162–169. doi: 10.1093/ndt/6.3.162. - DOI - PubMed
    1. Martinez I., Saracho R., Montenegro J., Llach F. A deficit of calcitriol synthesis may not be the initial factor in the pathogenesis of secondary hyperparathyroidism. Nephrol. Dial. Transplant. 1996;11:22–28. doi: 10.1093/ndt/11.supp3.22. - DOI - PubMed
    1. Levin A., Bakris G.L., Molitch M., Smulders M., Tian J., Williams L.A., Andress D.L. Prevalence of abnormal serum vitamin D, PTH, calcium and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int. 2007;71:31–38. doi: 10.1038/sj.ki.5002009. - DOI - PubMed
    1. Craver L., Marco M.P., Martinez I., Rue M., Borras M., Martin M.L., Sarro F., Valdivielso J.M., Fernandez E. Mineral metabolism parameters throughout chronic kidney disease stages 1–5—Achievement of K/DOQI target ranges. Nephrol. Dial. Transplant. 2007;22:1171–1176. doi: 10.1093/ndt/gfl718. - DOI - PubMed

LinkOut - more resources